To include your compound in the COVID-19 Resource Center, submit it here.

LJP 394: Phase III

LJPC said approximately 280 lupus patients have been enrolled thus far in the company's North American and European

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE